Original research articleRelationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease
References (36)
Oral contraceptives and hypertension
Lancet
(1967)Oral contraception and elevated blood pressure
Am J Obstet Gynecol
(1968)- et al.
Alterations in blood pressures associated with combined alcohol and oral contraceptive use: The Lipid Research Clinics Prevalence Study
J Chron Dis
(1982) - et al.
Plasma renin substrate, renin activity and aldosterone levels in a sample of oral contraceptive users from a community survey
Am Heart J
(1984) - et al.
Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk
Am J Obstet Gynecol
(1994) - et al.
A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol
J Lipid Res
(1978) - et al.
Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure
J Lipid Res
(1982) - et al.
Differential effects of transdermal estradiol and sequential progestogens on impedance to flow within the uterine arteries of postmenopausal women
Fertil Steril
(1992) Cardiovascular actions of insulin in humans. Implications for insulin sensitivity and vascular tone
Bailliere's Clin Endocrinol Metab
(1993)- et al.
Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions
Am Heart J
(1987)
Oral contraceptives, renin, aldosterone and high blood pressure
JAMA
Hypertension induced by oral contraceptives containing estrogen and gestagen: effects on plasma renin activity and aldosterone excretion
Ann Intern Med
Blood pressure in women after one year of oral contraception
Lancet
Oral contraceptives and hypertension
Br Heart J
Oral contraceptives and blood pressure
JAMA
Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives
Lancet
Blood pressure changes and oral contraceptive use: A study of 2676 black women in the Southeastern United States
Am J Epidemiol
Chronic disease in former college students. 1. Early precursors of fatal coronary heart disease
Am J Epidemiol
Cited by (49)
Hypertension and contraception
2019, Presse MedicaleProspective measurement of blood pressure and heart rate over 24 h in women using combined oral contraceptives with estradiol
2014, ContraceptionCitation Excerpt :Studies conducted performing office BP measurements have shown that preparations containing higher (≥ 50 μg) doses of ethinyl-estradiol (EE) may increase BP up to 15 mmHg [1,2]. Increases of about 4–5 mmHg BP have been documented with COCs containing lower EE doses [3–5] and confirmed by the few data performed with ambulatory 24-h BP monitoring [6,7]. Even the administration of EE-based hormonal contraceptive with vaginal ring induces an increase of 24-h BP of about 2 mmHg [8].
Modification of 24-h ambulatory blood pressure and heart rate during contraception with the vaginal ring: A prospective study
2013, ContraceptionCitation Excerpt :Values of nighttime heart rate remained unmodified (Fig. 2). Most studies have shown that, in nonhypertensive women, the administration of OCs increases BP [10–16]. These results are reinforced by data performed with a 24-h ambulatory monitoring [26,27].
Combined oral contraceptive containing drospirenone does not modify 24-h ambulatory blood pressure but increases heart rate in healthy young women: Prospective study
2013, ContraceptionCitation Excerpt :For this reason, OCs are contraindicated in women with hypertension [8,9]. In nonhypertensive women, OCs with high (50 mcg or more) [6,7], but also with low, EE dose may elevate office blood pressure [8–15], although inconsistently [16–18]. Furthermore, in the few studies performed with 24-h ambulatory monitoring, an increase in blood pressure has been consistently reported during OC use [19–21].
Effects of combined oral contraceptives containing levonorgestrel or chlormadinone on the endothelium
2013, ContraceptionCitation Excerpt :Turning to SAP, intergroup evaluation revealed a statistically significant 3% fall among EE/LNG users compared to controls, who experienced a 2% rise during this period Although all of these changes were statistically significant, they were likely of little clinical relevance since these reductions were always less than 10%. Chronic use of COCs can induce increases in arterial pressure [38–40], primarily by activating the renin–angiotensin system [41]. This increase in arterial pressure manifests primarily as SAP, with no significant effect on DAP [42].
Oral Contraceptives, Hormone Replacement Therapy, and Hypertension
2007, Comprehensive Hypertension